膀胱尿路上皮癌患者血浆及癌组织单核细胞趋化蛋白1表达的研究  

Expression of MCP1 gene in serum and tumor tissues in bladder urothelial carcinoma patients and its clinical significance

作　　者：白鑫[1] 高健刚[1] 侯四川[1] 孙小庆[1] 朱磊一[1] 

机构地区：[1]青岛市市立医院东院泌尿外科,266071

出　　处：《肿瘤研究与临床》2011年第8期538-540,共3页Cancer Research and Clinic

基　　金：青岛市科技局基金（2007-K2D18）

摘　　要：目的探讨膀胱尿路上皮癌（BTCC）血浆及癌组织中单核细胞趋化蛋白1（MCP1）基因的表达与膀胱癌发病机制的相关性。方法BTCC患者30例，男20例，女10例，分别取血浆和膀胱癌及癌旁组织标本。对照组为非肿瘤患者30例，男20例，女10例，取血液标本。酶联免疫吸附（ELISA）法测血浆中MCP1浓度，免疫组织化学SP法检测组织MCP1的表达情况。实时荧光定量PCR法检测MCP1mRNA表达水平。比较2组资料，分析膀胱癌临床特点与MCP1表达的关系。结果BTCC组患者血浆中MCP1浓度为（193．4±105．7）Pg／ml，高于非肿瘤组的（91．8±34．6）Pg／ml（t=8．37，P〈0．001）；BTCC组中浸润性患者MCP1血浆浓度为（204．3-4-167．5）Pg／ml，高于表浅性患者的（130．6±69．2）Pg／ml（t=2．667，P=0．013）。免疫组织化学显示BTCC组织中MCP-1表达阳性率为70．0％（21／30），癌旁组织为43．3％（13／30），二者间差异有统计学意义（X^2=4．9，P〈0．05）；BTCC组中浸润性者表达阳性率为80．0％（8／10），高于表浅性的65．0％（13／20）。膀胱癌组织中MCP-1的阳性强度也明显高于对照组；BTCC组中浸润性者高于表浅性者。膀胱癌组织MCP-1总RNA和mRNA水平与对照组比较差异有统计学意义（X^2=10．08，P〈0．05）。结论MCP1基因表达上调可能在BTCC的发生及转移中发挥重要作用。Objective To investigate the monocyte chemoattractant protein （MCP1） gene expression of the bladder urothelial carcinoma and its correlation with the pathogenesis of the bladder urothelial carcinoma. Methods Thirty cases of patients with the bladder urothelial carcinoma, including 20 cases of male and 10 cases of female, were taken the blood and bladder tissue. In control group, 30 cases of non-cancer patients, including 20 cases of male and 10 cases of female, were taken the blood samples. ELISA method was used to detected the concentration of plasma MCP1, immunohistochemical method to investigate the expression of MCPI in the bladder urothelial carcinoma and adjacent tissues. Real-time quantitative RT-PCR was applied to detected the expression of MCP1. Data of the two groups were comparied and the relationship between the expression of MCP1 and the clinical characteristics of the bladder urothelial carcinoma was analyzed. Results MCP1 in group of patients with the bladder urothelial carcinoma was （193.4±105.7） pg/ml, and higher than that in non-tumor group （91.8±34.6） pg/ml （t = 8.37, P 〈0.001）. MCP1 in invasive bladder cancer was （204.3± 167.5） pg/ml and superficial bladder cancer was （130.6±69.2） pg/ml （t = 2.667, P = 0.013）. By immunohistochemistry, the MCP-1 positive rate in the bladder urothelial carcinoma was 70.0 % （21/30）, that in adjacent cancer tissue was 43.3 % （13/30） （X^2 = 4.9, P 〈0.05）. The positive rate of MCP1 in invasive bladder cancer in tumor group was 80.0 % （8/10） and that in superficial bladder cancer was 65.0 %（13/20）. At the same time, MCP-I positive intensity in the bladder urothelial carcinoma was significantly higher than that in adjacent tissues. The intensity in invasive bladder cancer was higher than that in superficial ones. Total RNA and mRNA levels of MCP-1 in the bladder urothelial carcinoma were statistically differences compared with that in adjacent tissues （X^2 = 10.08, P 〈0.05）. Conclusion The upregulation of M

关 键 词：膀胱肿瘤 趋化因子CCL2 基因 

分 类 号：R737.14[医药卫生—肿瘤]